Ask HopeStage to review this study with me
Study ID: NCT06605105. We help you review the study, but cannot decide medical eligibility.
Enrolling By InvitationNCT06605105
A Phase III Long-Term Extension study With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in people with Major Depressive Disorder (EXTEND)
This study is enrolling by invitation in the United States and in Australia. It focuses on depression.
DepressionDrugFrom 18 Years to 85 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing depression.
What would participation involve?
Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Australia and in the United States.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a clinic, with sites including Combined Research Orlando in Phoenix, Open Mind Collective / UCSF Medical Center - Mount Zion in San Francisco, and Mountain View Clinical Research in Denver. Participation appears to involve using a digital tool or support program and giving feedback through check-ins or assessments. The main fit is usually being able to understand the study and consent and having a stable enough treatment background for the study, while common reasons not to take part include safety concerns that need urgent care first and active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: July 18, 2025
- Recruitment status
- Enrolling By Invitation
- Estimated enrollment
- Not clearly listed
- Sponsor
- Cybin IRL Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, Australia
- Age range
- From 18 Years to 85 Years
- Official registry ID
- NCT06605105
- Official title
- A Phase III Long-Term Extension Trial With Optional Additional Doses of CYB003 to Assess the Safety and Long-term Efficacy in Participants With Major Depressive Disorder (EXTEND)
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT06605105. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Australia.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring digital app or tool for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Cybin IRL Limited, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The recruitment status is not clearly listed. Check the official registry or contact the study team.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
Enrolling By InvitationNCT07161700
Safety study of SPT-300 (GlyphAllo) in depression
This study is enrolling by invitation in the United States, in Bulgaria, in Czechia, .... It is testing SPT-300 (GlyphAllo) for depression.
Enrolling By InvitationNCT07217860
An Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
This study is enrolling by invitation in the United States. It is testing azetukalner for depression.
Enrolling By InvitationNCT06922110
An Study of Azetukalner in Major Depressive Disorder
This study is enrolling by invitation in the United States. It is testing azetukalner for depression.